Kymera Therapeutics Inc
NASDAQ:KYMR

Watchlist Manager
Kymera Therapeutics Inc Logo
Kymera Therapeutics Inc
NASDAQ:KYMR
Watchlist
Price: 73.09 USD -2.25% Market Closed
Market Cap: 5.3B USD

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of KYMR.

The Intrinsic Value is calculated as the average of DCF and Relative values:

KYMR Intrinsic Value
Not Available
Base Case Scenario
Compare KYMR to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about KYMR?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Kymera Therapeutics Inc

Current Assets 528.3m
Cash & Short-Term Investments 505.7m
Other Current Assets 22.6m
Non-Current Assets 573.7m
Long-Term Investments 473.1m
PP&E 88.1m
Other Non-Current Assets 12.6m
Current Liabilities 71.6m
Accounts Payable 5.5m
Accrued Liabilities 40.2m
Other Current Liabilities 25.8m
Non-Current Liabilities 84.2m
Long-Term Debt 1.8m
Other Non-Current Liabilities 82.4m
Efficiency

Free Cash Flow Analysis
Kymera Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Kymera Therapeutics Inc

Revenue
43.7m USD
Operating Expenses
-372.1m USD
Operating Income
-328.4m USD
Other Expenses
33.3m USD
Net Income
-295.1m USD
Fundamental Scores

KYMR Profitability Score
Profitability Due Diligence

Kymera Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

19/100
Profitability
Score

Kymera Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

KYMR Solvency Score
Solvency Due Diligence

Kymera Therapeutics Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Kymera Therapeutics Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KYMR Price Targets Summary
Kymera Therapeutics Inc

Wall Street analysts forecast KYMR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KYMR is 111.78 USD with a low forecast of 70.7 USD and a high forecast of 144.9 USD.

Lowest
Price Target
70.7 USD
3% Downside
Average
Price Target
111.78 USD
53% Upside
Highest
Price Target
144.9 USD
98% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Kymera Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for KYMR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

KYMR Insider Trading
Buy and sell transactions by insiders

KYMR News

Other Videos